| Title： | Clinical practice guidelines for the diagnosis and treatment of inflammatory breast cancer 2022.V1（CSBrS-Guideline-21) |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | Chinese breast diseases specialists and related medical workers |
| Evidence classification method： | None |
| Development unit： | the Chinese Society of Breast Surgery (CSBrS) of the Chinese Medical Association |
| Registration time: | 2022-01-23 |
| Registration number： | IPGRP-2022CN046 |
| Purpose of the guideline: | In order to improve the clinical diagnosis and treatment of inflammatory breast cancer (IBC), the Chinese Medical Association Surgery Branch organized experts to put forward key clinical issues related to the clinical practice of IBC through literature research and discussion. Development and Evaluation) system to evaluate relevant evidence, and combined with clinical accessibility in China, the Chinese Medical Association IBC clinical practice guidelines are formulated, aiming to provide reference for Chinese breast cancer and other professional physicians. |
Latest registration
